Antisoma drug AS1404 found to selectively damage tumor blood vessels

By Angela McDaniels

Seattle, Nov. 1 - Antisoma said it presented data on its AS1404 drug for the treatment of cancer at the European Cancer Conference on Tuesday.

AS1404 works by damaging the blood vessels that sustain tumors, the company said. New trials examined the damaging effect by measuring the leakage of a dye into tissues from the bloodstream.

Antisoma said the trial provided new and direct evidence that AS1404 selectively disrupts tumor blood vessels while leaving those in healthy tissues unharmed.

The presentation followed the company's recent announcement of promising preliminary findings from a phase-2 trial of AS1404 in non-small cell lung cancer, which Antisoma said found that patients receiving AS1404 in addition to chemotherapy had a higher frequency of tumor responses and a lower frequency of progressive disease than patients receiving chemotherapy alone.

Antisoma is a pharmaceutical company based in London that develops cancer drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.